预测肝细胞癌合并门静脉癌栓患者钇-90放射栓塞治疗反应的预后评分开发
这项单中心回顾性研究纳入2010至2015年连续接受钇-90经动脉放射栓塞(TARE)的肝细胞癌合并门静脉癌栓患者120例,中位总生存期14.1个月,中位无进展生存期6.5个月;胆红素、门静脉癌栓延伸范围和肿瘤负荷是独立预后因素,据此构建的三类预后评分可区分不同生存结局。
要点
- 胆红素、门静脉癌栓延伸范围和肿瘤负荷是总生存期的独立相关变量。
- 预后评分分为有利(0分)、中等(2-3分)和极差(>3分)三组。
- 三组中位总生存期分别为32.2、14.9和7.8个月(p<0.0001)。
核心结论
- 钇-90放射栓塞是肝细胞癌合并门静脉癌栓患者的有效治疗。
- 所提出的预后分层可能有助于更好地识别适合该治疗的良好候选者以及TARE可能无效的患者。
研究设计与样本
- 单中心回顾性研究,为期六年(2010-2015年),纳入连续接受TARE的患者。
- 纳入标准:至少一个可测量肝细胞癌、存在未闭塞门静脉主干的癌栓、无肝外转移、Child-Pugh评分在B7以内、美国东部肿瘤协作组体能状态0-1。
- 采用单变量和多变量分析探索与生存期独立相关的变量,并推导预后评分,识别出三个预后类别。
- 共纳入120例患者。
主要发现
- 中位总生存期为14.1个月(95% CI 10.7-17.5),中位无进展生存期为6.5个月(95% CI 3.8-9.2)。
- 与总生存期独立相关的变量仅为胆红素、门静脉癌栓延伸范围和肿瘤负荷。
- 三个预后类别:有利预后(0分)、中等预后(2-3分)和极差预后(>3分)。
- 三个类别的中位总生存期分别为32.2个月、14.9个月和7.8个月(p<0.0001)。
- 无进展生存期(p=0.045)和肝功能失代偿风险(p<0.0001)在同一预后分类中也存在显著差异。
关键数值与推荐
- 预后评分类别:有利预后0分,中等预后2-3分,极差预后>3分。
- 三个类别的中位总生存期分别为32.2个月、14.9个月和7.8个月(p<0.0001)。
- 无进展生存期在同一预后分类间差异p=0.045,肝功能失代偿风险差异p<0.0001。
临床怎么用
- 作者认为所提出的预后分层可能有助于更好地识别适合TARE的良好候选者以及TARE可能无效的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Yttrium-90 transarterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC), associated with portal vein tumor thrombus (PVTT). The aim of this study is to identify prognostic factors for survival in patients with HCC and PVTT undergoing TARE, and build a prognostic classification for these patients. METHODS: This is a single center retrospective study conducted over six years (2010-2015), on consecutive patients undergoing TARE. Patients were included if they met the following criteria: presence of at least one measurable HCC, presence of PVTT not occluding the main portal trunk, absence of extrahepatic metastases, Child-Pugh score within B7, Eastern Cooperative Oncology Group performance status 0-1. Uni- and multivariable analysis was used to explore the variables that showed an independent relationship with survival. A prognostic score was then derived, and three prognostic categories were identified. RESULTS: A total of 120 patients were included in the study. Median overall survival (OS) was 14.1 months (95% CI 10.7-17.5) and median progression-free survival (PFS) was 6.5 months (95% CI 3.8-9.2). The only variables independently correlated with OS were bilirubin, extension of PVTT and tumor burden. Three prognostic categories were identified: favourable prognosis (0 points), intermediate prognosis (2-3 points) and dismal prognosis (>3 points). Median OS in the three categories was 32.2 months, 14.9 months and 7.8 months respectively (p <0.0001). PFS (p = 0.045) and the risk of liver decompensation (p <0.0001) also significantly differed along the same prognostic categories. CONCLUSIONS: Radioembolization with Yttrium-90 is an effective therapy for patients with HCC and PVTT. The proposed prognostic stratification may help to better identify good candidates for the treatment, and those for whom TARE may be futile. LAY SUMMARY: Yttrium-90 transarterial radioembolization (TARE) is a microembolic procedure that minimizes alterations to hepatic arterial flow, and thus can be safely performed in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). In this study, we retrospectively evaluated the independent predictors of long-term outcomes in patients with HCC and PVTT treated with TARE. Bilirubin level, extension of PVTT and tumor burden were independently related to post-treatment survival: the combination of these factors allowed us to build a prognostic stratification that may help to better identify good candidates for the treatment, and those for whom TARE may be futile.
引用
- Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018. PMID: 29331342. doi:10.1016/j.jhep.2017.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。